 |
Tim Wollaeger
Chairman of the Board
Timothy Wollaeger has more than 30 years' experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling Ventures as a Managing Director in 2002, and opened the firm's San Diego office. Mr. Wollaeger serves on the board of directors for several Sanderling portfolio companies, including Asteres, Sotera Wireless, CalciMedica and REN. He is Chairman of the Board of Directors for Chimerix and is Chairman and Chief Executive Officer of Harkness Pharmaceuticals.
Prior to joining Sanderling in 1994, Mr. Wollaeger founded the venture capital firm Kingsbury Capital Partners. At Kingsbury, seed and early stage investing was combined with active management and portfolio companies included Aurora Biosciences, Amylin Pharmaceuticals (NASDAQ: AMLN), Senomyx (NASDAQ: SNMX), and Althea Technologies. He was named E&Y San Diego’s Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001.
Prior to Kingsbury Capital Partners, Mr. Wollaeger helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the board of directors until 1994. In 1986, Mr. Wollaeger became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found Pyxis, Biosite, Amlin Pharmaceuticals (NASDAQ: AMLN) and Vical (NASDAQ: VICL). All four of these companies became public. Pyxis was acquired by Cardinal Health in 1996 for $1 billion and Biosite was acquired by Inverness Medical Innovations Inc. in 2007 for $1.7 billion.
In 1983, Mr. Wollaeger joined Hybritech, Inc., San Diego's first biotechnology company, as Vice President and Chief Financial Officer until Hybritech was acquired by Eli Lilly & Co. (NYSE: LLY) in 1986.He began his life science career at Baxter International where he was Manager of Operations Analysis. His last position was Vice President and General Manager of the Company's operations in Mexico.
Mr. Wollaeger earned a bachelor’s degree in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned a master’s degree in business administration from The Stanford Graduate School of Business in 1971.
|
|
|
|
Dr. Allan Marchington
Partner
Allan is in charge of Apposite's LIfe Sciences investments. A partner at Apposite since its inception, Allan is a proven entrepreneur and executive in the pharmaceuticals sector and currently sits on the Board of the UK BioIndustry Association.
Previously, Allan was at Abingworth Management, where he made strategic changes to several of their portfolio companies. Allan joined Abingworth in 2003, from Millennium Pharmceuticals, Cambridge, Mass., where as a member of the senior management team, he was responsible for Millennium's European activities and of all the company's technology investments.
Prior to Millennium. he was a principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company that was acquired by Millennium for a substantial multiple of invested capital. Before setting up Cambridge Combinatorial, Allan worked for seven years in a range of therapeutic areas at Pfizer, Sandwich. He has a PhD in Chemistry from the University of Liverpool.
|
|
 |
Kenneth Buechler, Ph.D.
Director
Kenneth Buechler, Ph.D., was most recently President, Chief Scientific Officer and co-founder of Biosite Incorporated. Dr. Buechler is a co-inventor of certain Biosite proprietary technologies, including the Biosite® Drugs of Abuse Panel and the Biosite Meter Plus platform. From 1988 to 1994, Dr. Buechler was Biosite’s Director of Chemistry. Prior to forming Biosite, he was a senior research scientist for the Diagnostics Research and Development Group at Hybritech Incorporated in San Diego. As a Senior Research Scientist, he was responsible for new product development and was the transfer project leader for ICON® QSR CK-MB, a cardiac marker assay. In addition, he was responsible for the design and synthesis of reagents for use in the first rapid, visual pregnancy test, the ICON® hCG test.
Dr. Buechler received his Ph.D. in biochemistry and his bachelor’s degree in chemistry from Indiana University. He is a member of the American Chemical Society, the Biochemical Society, the International Federation of Clinical Chemistry and Laboratory Medicine and the American Association of Clinical Chemists.
|
|
 |
Eric Topol, M.D.
Director
Eric Topol, M.D. is the Director of the Scripps Translational Science Institute, a National Institutes of Health funded program of the Clinical and Translational Science Award (CTSA) Consortium. He is Professor of Translational Genomics at The Scripps Research Institute, the Chief Academic Officer of Scripps Health, and a Senior Consultant cardiologist practitioner at Scripps Clinic.
Prior to joining Scripps, D.Topol served on the faculty of Case Western as a professor in genetics, chaired the Department of Cardiovascular Medicine at Cleveland Clinic for 15 years and raised its status to rank #1 by US News and World Report for 11 consecutive years, he also founded the Cleveland Clinic Lerner College of Medicine. His work in the genomics of heart attack led to the discovery of key genes (MEF2A deletion, THSB-4 variant) which earned recognition by the American Heart Association as top 10 research advances in 2002 and 2004. As a leader in clinical trials of novel therapeutics, he administered recombinant t-PA to the first patient in 1984, pioneered and led the clinical development of clopidogrel (Plavix), bivalirudin (Angiomax), and abciximab (ReoPro).
Dr.Topol has over 1000 original peer reviewed publications and has edited over 30 books, including the Textbook of Interventional Cardiology (5th ed), and the Textbook of Cardiovascular Medicine (3rd ed). He has been elected to the Institute of Medicine of the National Academy of Sciences, the American Association of Physicians and recognized by the Institute of Scientific Information (ISI) as one of the top 10 cited biomedical researchers in medicine in the past decade.
|
|
 |
Bobby Kandaswamy
Board Observer
Mr. Kandaswamy joined Intel Capital in 1999 and works closely with Intel’s Digital Health Group and the Corporate Technology Groups’ Communications Technology Lab and Personal Health team. Prior to Intel Capital, Bobby was a Senior Manager driving new business initiatives at Cardinal Health, a global leader in medical and surgical products (NYSE: CAH). Before that Bobby worked at Baxter Healthcare (NYSE: BAX) in business development and product development roles.
Bobby is currently a board observer at Grid Net, Life Masters, PacketMotion and Sotera Wireless. He has also invested in and managed exits at FutureSoft (acquired by Flextronics), IP Infusion (acquired by Access) and NetScaler (acquired by Citrix). Bobby has a master’s degree in business administration from J.L. Kellogg Graduate School of Management and a master of science degree in industrial engineering from Northern Illinois University.
|
|
 |
Nagraj Kashyap
Board Observer
Nagraj Kashyap is a Vice President at Qualcomm and heads up worldwide activities for Qualcomm Ventures. Mr. Kashyap has over 14 years of experience in the telecommunications industry. Prior to his current role, Nagraj worked in various engineering and management capacities at Nortel, 3COM, Motorola, PRTM and Qualcomm.
Mr. Kashyap currently actively manages and serves as a board member or observer for Qualcomm Ventures investments in Zeebo, Obopay, WaveMarket, Airplay Networks, GoTV Networks, Sotera Wireless, and Novarra. Mr. Kashyap also led Qualcomm Ventures investments in Airvana (AIRV) and Bitfone (acquired by HP in 2007). Mr. Kashyap has a master’s degree in business administration from the J.L. Kellogg Graduate School of Management and a master of science degree in computer science from the University of Texas at Austin.
|
|
|
|
|
|
|
